313 related articles for article (PubMed ID: 14571488)
1. Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: findings from the global registry of acute coronary events (GRACE).
Montalescot G; Van de Werf F; Gulba DC; Avezum A; Brieger D; Kennelly BM; Mazurek T; Spencer F; White K; Gore JM;
Catheter Cardiovasc Interv; 2003 Nov; 60(3):360-7. PubMed ID: 14571488
[TBL] [Abstract][Full Text] [Related]
2. Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).
Brieger D; Van de Werf F; Avezum A; Montalescot G; Kennelly BM; Granger CB; Goodman SG; Dabbous OH; Agnelli G;
Am Heart J; 2007 Jun; 153(6):960-9. PubMed ID: 17540196
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
5. Early discharge is feasible following primary percutaneous coronary intervention with transradial stent implantation under platelet glycoprotein IIb/IIIa receptor blockade. Results of the AGGRASTENT Trial.
Dirksen MT; Ronner E; Laarman GJ; van Heerebeek L; Slagboom T; van der Wieken LR; van der Wouw PA; Kiemeneij F
J Invasive Cardiol; 2005 Oct; 17(10):512-7. PubMed ID: 16204742
[TBL] [Abstract][Full Text] [Related]
6. The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Lee DS; Bhatt DL; Moliterno DJ; Peacock WF; Ellis SG; Topol EJ
J Invasive Cardiol; 2004 Feb; 16(2):46-51. PubMed ID: 14760188
[TBL] [Abstract][Full Text] [Related]
7. Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?
Piamsomboon C; Wong PM; Mathur A; Singh D; Liu MW; Baxley WA; Iyer SS; Dean LS; Roubin GS
Catheter Cardiovasc Interv; 1999 Apr; 46(4):415-20. PubMed ID: 10216005
[TBL] [Abstract][Full Text] [Related]
8. Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
Karha J; Gurm HS; Rajagopal V; Fathi R; Bavry AA; Brener SJ; Lincoff AM; Ellis SG; Bhatt DL
Am J Cardiol; 2006 Oct; 98(7):906-10. PubMed ID: 16996871
[TBL] [Abstract][Full Text] [Related]
9. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
[TBL] [Abstract][Full Text] [Related]
10. Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.
Dabbous OH; Anderson FA; Gore JM; Eagle KA; Fox KA; Mehta RH; Goldberg RJ; Agnelli G; Steg PG;
Heart; 2008 Feb; 94(2):159-65. PubMed ID: 17575335
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of glycoprotein IIb/IIIa inhibitor use during primary coronary angioplasty: results of propensity analysis using the New York State Percutaneous Coronary Intervention Reporting System.
Srinivas VS; Skeif B; Negassa A; Bang JY; Shaqra H; Monrad ES
Am J Cardiol; 2007 Feb; 99(4):482-5. PubMed ID: 17293189
[TBL] [Abstract][Full Text] [Related]
12. Rheolytic thrombectomy and platelet glycoprotein IIb/IIIa blockade for stent thrombosis.
Rinfret S; Cutlip DE; Katsiyiannis PT; Ho KK; Cohen DJ; Carrozza JP; Laham RJ
Catheter Cardiovasc Interv; 2002 Sep; 57(1):24-30. PubMed ID: 12203922
[TBL] [Abstract][Full Text] [Related]
13. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
[TBL] [Abstract][Full Text] [Related]
14. Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality.
Witkowski A; Maciejewski P; Wasek W; Malek LA; Niewada M; Kaminski B; Drzewiecki J; Kosmider M; Kubica J; Ruzyllo W; Peruga JZ; Dudek D; Opolski G; Dobrzycki S; Gil RJ;
Eur Heart J; 2009 Jul; 30(14):1736-43. PubMed ID: 19376786
[TBL] [Abstract][Full Text] [Related]
15. Safety of glycoprotein IIb/IIIa inhibitors in urgent or emergency coronary artery bypass graft surgery.
Cheng DK; Jackevicius CA; Seidelin P; Feindel C; Rouleau JL
Can J Cardiol; 2004 Feb; 20(2):223-8. PubMed ID: 15010747
[TBL] [Abstract][Full Text] [Related]
16. [Percutaneous coronary interventions in elderly patients: clinical indications and adjunctive medical treatment. The Italian Drug Evaluation in Angioplasty (IDEA) study].
Bossi I; Piccaluga E; Scatturin M; Corvaja N; Pasquetto G; Steffanon L; Oberhollenzer R; Colombo P; Bolognese L; Savonitto S
G Ital Cardiol (Rome); 2006 Feb; 7(2):136-44. PubMed ID: 16532725
[TBL] [Abstract][Full Text] [Related]
17. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization.
Lenzen MJ; Boersma E; Bertrand ME; Maier W; Moris C; Piscione F; Sechtem U; Stahle E; Widimsky P; de Jaegere P; Scholte op Reimer WJ; Mercado N; Wijns W;
Eur Heart J; 2005 Jun; 26(12):1169-79. PubMed ID: 15802360
[TBL] [Abstract][Full Text] [Related]
18. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.
Sabatine MS; Morrow DA; Giugliano RP; Murphy SA; Demopoulos LA; DiBattiste PM; Weintraub WS; McCabe CH; Antman EM; Cannon CP; Braunwald E
Circulation; 2004 Feb; 109(7):874-80. PubMed ID: 14757697
[TBL] [Abstract][Full Text] [Related]
19. Decreased complication rates using the transradial compared to the transfemoral approach in percutaneous coronary intervention in the era of routine stenting and glycoprotein platelet IIb/IIIa inhibitor use: a large single-center experience.
Eichhöfer J; Horlick E; Ivanov J; Seidelin PH; Ross JR; Ing D; Daly P; Mackie K; Ridley B; Schwartz L; Barolet A; Dzavík V
Am Heart J; 2008 Nov; 156(5):864-70. PubMed ID: 19061699
[TBL] [Abstract][Full Text] [Related]
20. Primary coronary intervention in acute myocardial infarction.
Kim CX; Davidson CJ
Ital Heart J; 2004 Jun; 5 Suppl 6():76S-82S. PubMed ID: 15185919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
